All good things must eventually come to an end, and so it is withATL's Ultramark 4 ultrasound scanner. After a 12-year run in whichover 12,000 systems were installed, the Bothell, WA, company hasdiscontinued U.S. production of the workhorse ob/gyn
All good things must eventually come to an end, and so it is withATL's Ultramark 4 ultrasound scanner. After a 12-year run in whichover 12,000 systems were installed, the Bothell, WA, company hasdiscontinued U.S. production of the workhorse ob/gyn scanner.
ATL introduced Ultramark 4 in 1984 as a general-purpose, non-color-flowscanner. Sales of the systems were shifted to ob/gyn physiciansand international markets as the vendor developed more advancedscanners. The scanner sold for $30,000 to $60,000, depending onconfiguration.
U.S. production of Ultramark 4 was stopped early this year,although manufacturing and sales will continue in India throughATL's joint venture company in that country.
A major factor contributing to the scanner's demise was thechanging face of the U.S. market, which has resulted in fewersolo ob/gyn practitioners and more group practices that can affordmore advanced technology, according to ATL spokesperson Jane Hedberg.
"We feel that the ob/gyn market is going to more of agroup practice situation," Hedberg said. "Ultramark4 was a very successful product for us, but the technology hasimproved since then and it is time to provide more image qualityand more features."
While the entire ATL sales force sold Ultramark 4 scanners,the majority of sales were handled by a 15-person ob/gyn salesteam. Those employees will be folded into a new sales force ATLhas established, which is targeted at women's health.
To fill Ultramark 4's place in the gray-scale imaging segment,ATL is rolling out an upgraded version of the Apogee 800 scanner,which the company acquired through its purchase of Interspec.Apogee 800 Plus features a new user-friendly control panel, anew microprocessor, and new and expanded analysis packages, Hedbergsaid. It will begin shipping next month at list prices of $65,000for a gray-scale scanner to $90,000 for a color version.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.